CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 136 enrolled
Drug / intervention
KAD-1229drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01333592
NCT01333592Phase 3Completed
CompareCT.gov

A Multicenter, Open Label, Long-term Study of KAD-1229 in Type 2 Diabetes Patients Who Show Inadequate Glycemic Control With Diet, and Biguanide or DPP-4 Inhibitor Monotherapy

Kissei Pharmaceutical Co., Ltd.·interventional·Posted Apr 12, 2011·Updated Dec 15, 2014

In Brief

A Phase 3 clinical trial evaluating KAD-1229 for Type 2 Diabetes. Completed, enrolled 136 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the long-term safety and efficacy of KAD-1229 as combination therapy with biguanide or DPP-4 inhibitor in type 2 diabetes patients who show inadequate glycemic control with diet, and biguanide or DPP-4 inhibitor monotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 12, 2011
Primary CompletionAug 1, 2012
Study CompletionNov 1, 2012
TodayJul 2, 2026
Posted 15.2 years ago

Interventions

KAD-1229drug